GPR-001: Inflammatory pain & sickle-cell vaso-occlusive crisis
A small-molecule program targeting GPR55 to address inflammatory pain and sickle-cell vaso-occlusive crises.
Program Overview
Scientific Rationale
A non-opioid pain mechanism
GPR55 is a G-protein-coupled receptor implicated in inflammation and pain signaling. Modulating it offers a potential route to treating inflammatory pain without relying on opioids.
Sickle-cell crises
Painful vaso-occlusive crises in sickle cell disease are driven in part by inflammation. A GPR55-targeted small molecule aims to reduce the frequency and severity of these episodes.
Our Approach
AI-guided discovery
Omic designed and prioritized GPR55-targeting molecules using its platform, with digital patient models predicting response across patient backgrounds.
Where it stands
The program is in lead optimization, optimizing potency, selectivity, and oral drug-like properties.
Program details, including specific molecular targets, are disclosed selectively under confidentiality as part of partnership and licensing discussions.
Interested in Licensing GPR-001?
Contact us to discuss licensing opportunities and partnership terms